Table 1.
Characteristics of the included studies.
| Author | Local | Registration | Abbreviations | Sample size | EC Type | Age, years | Targeted agents | CRT regimens | CRT phase | Total dose of radiation | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Kelly et al. (22) | Multilateral | NCT02743494 | Checkmate 577 | 794 | Esophageal or gastroesophageal junction cancer | 62 (26–86) | Nivolumab | Platinum with paclitaxel(or fluorouracil),radiation | Neoadjuvant | 45 Gy | 45 Months |
| Rades et al. (23) | Germany | NCT01787006 | LEOPARD-II | 68 | Non-metastatic esophageal carcinoma | 64(44-80) | Cetuximab | Cisplatin,fluorouracil,radiation | Definitive | 59.4 Gy | 2 Years |
| Xie et al. (24) | China | NCT00686114 | NA | 352 | Esophageal squamous cell carcinoma | 61(35-69) | Erlotinib | Paclitaxel,cisplatin,radiation | Definitive | 60 Gy | 10 Years |
| Ruhstaller et al. (25) | Multilateral | NCT01107639 | SAKK 75/08 | 300 | Esophageal carcinoma | 61(53-68) | Cetuximab | Docetaxel,cisplatin,radiation | Neoadjuvant | 45 Gy | 5 Year |
| de Castro Junior et al. (26) | Brazil | NCT01249352 | NICE | 107 | Locally advanced esophageal carcinoma | 59(35.4-81.4) | Nimotuzumab | Cisplatin,fluorouracil,radiation | Definitive | 50.4 Gy | Open |
| Suntharalingam et al. (27) | US | NCT00655876 | RTOG0436 | 344 | Esophageal carcinoma | 64(32-87) | Cetuximab | Paclitaxel,cisplatin,radiation | Definitive | 50.4 Gy | Open |
| Crosby et al. (28) | UK | ISRCTN:47718479 | SCOPE-1 | 258 | Non-metastatic esophageal carcinoma | 66.7(IQR:60.9-72.9)# | Cetuximab | Cisplatin,capecitabine,radiation | Definitive | 50 Gy | Open |
| Lv et al. (29) | China | ChiCTR-TRC-13003908 | NA | 63 | Locally advanced esophageal squamous cell carcinoma | NA | Endostatin | Docetaxel,cisplatin,radiation | Definitive | 60-66 Gy | 2 Year |
| Li et al. (30) | China | NA | NA | 37 | Esophageal squamous cell carcinoma | NA | Endostatin | Docetaxel,cisplatin,radiation | Definitive | 60-66 Gy | NA |
| Ramos-Suzarte et al. (31) | Cuba | NA | NA | 68 | Advanced esophageal carcinoma | 58.8(54.8-62.8) | Nimotuzumab | Cisplatin,fluorouracil,radiation | Definitive | 75.6 Gy | NA |
NA, not-available; CRT, chemoradiotherapy; EC, esophageal cancer.
#interquartile range.